Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

Gasslitter, Irina and Kirsten, Natalia and Augustin, Matthias and Torz, Kaspar and Mrowietz, Ulrich and Eyerich, Kilian and Puig, Lluís and Hoetzenecker, Wolfram and Schütz-Bergmayr, Martina and Weger, Wolfgang and Wolf, Peter and Reider, Norbert and Ratzinger, Gudrun and Papageorgiou, Karolina and Meier, Thomas O. and Maul, Julia-Tatjana and Anzengruber, Florian and Navarini, Alexander A.. (2019) Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Archives of Dermatological Research, 311 (5). pp. 421-424.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/72186/

Downloads: Statistics Overview


IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients' PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.
Faculties and Departments:03 Faculty of Medicine > Bereich Spezialfächer (Klinik) > Dermatologie USB > Dermatologie (Navarini)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Spezialfächer (Klinik) > Dermatologie USB > Dermatologie (Navarini)
UniBasel Contributors:Navarini, Alexander
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:09 Jul 2020 16:03
Deposited On:09 Jul 2020 16:03

Repository Staff Only: item control page